Investing Profile

Michael Aberman

InvestorVC
General Partner at Regeneron Ventures
Photo of Michael Aberman, General Partner at Regeneron Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
The Wharton School Network
818 CONNECTIONS
Morgan Stanley Network
697 CONNECTIONS
Cornell University Network
384 CONNECTIONS
Credit Suisse Network
311 CONNECTIONS
My Perfect Sale (acquired by Sugar, Inc) Network
131 CONNECTIONS
cb
Regeneron Ventures General Partner
$100K - $2.0M
$1M
1
CompanyStageDateRound SizeTotal Raised
Tasca
Series ADec 2024$48M
$48M
Resident NewYork-Presbyterian HospitalPresent
Senior Director, Business Development AntigenicsPresent
Biotech Analyst Morgan StanleyPresent
Biotech Analyst Credit SuissePresent
Senior Vice President, Strategy and Investor Relations RegeneronPresent
Board Member Rover DiagnosticsPresent
SeniorAdvisor ImmunaiPresent
Board Member Unnatural Products Inc.Present
Board Member Unnatural ProductsPresent
Business Advisor Excision BioTherapeuticsPresent
Board Member My Perfect Sale (acquired by Sugar, Inc)Present
Board Member XenImmune Therapeutics, Inc.Present
President and CEO My Perfect Sale (acquired by Sugar, Inc)Present
President and CEO Quentis Therapeutics, IncPresent
General Partner My Perfect Sale (acquired by Sugar, Inc)Present
General Partner Regeneron VenturesPresent
Cornell University BA Biology
University of Toronto MD Medicine
The Wharton School MBA Healthcare
Sign in with Google →
Sign in with Google →